Abstract 1243

Background.

Accurate identification of the causative organism in invasive pulmonary aspergillosis (IPA) is important for both epidemiological reasons and optimal management of patients (pts); therefore, it is now recommended. The most efficient strategy to isolate the fungus, however, is not well-established. The reported mycological yield of bronchoscopy, the most commonly used noninvasive approach, does not exceed 40–60%. In the context of IPA, we investigated whether a mycological diagnostic strategy could be optimized based on pt characteristics.

Methods.

We used a database of 57 pts with IPA enrolled between May 2005 and February 2007 in a prospective multicenter study primarily designed to determine the performance of several microbiological tools in predicting the outcome of IPA. The study protocol was approved by the ethics committee of Saint-Louis Hospital, and all pts provided informed consent. Statistical methods: Predictive factors of positive microbiological results (cytology and/or culture) were analyzed by Fisher's exact test and multiple regression models. Whenever necessary, groups of pts were compared by Fisher's exact test. Analyses were carried out using R version 2.6.2 statistical software (the R Foundation for Statistical Computing, Vienna, Austria).

Pt and IPA characteristics according to the underlying condition.

CharacteristicsAllogeneicstem celltransplantationN=23AcuteleukemiaN=23OtherN=11
Female gender (%) 8 (35) 15 (65) 4 (36) 
Age, years 37 (10 to 78) 53 (16 to 72) 64 (45 to 72) 
Type of diagnosis (%)    
Proven 2 (9) 1 (4) 1 (9) 
Probable 20 (87) 14 (61) 10 (91) 
Possible 1 (4) 8 (35) 0 (0) 
Concomitant lung infection (%) 11 (48) 1 (4) 4 (36) 
Bacterial 
Viral 
Fungal 
Corticosteroids (%) 19 (83) 6 (26) 6 (55) 
Absolute neutrophil count (ANC)/mm3 (%)    
<100 7 (30) 18 (78) 2 (18) 
100-500 5 (22) 1 (4) 4 (36) 
>500 11 (48) 4 (17) 5 (45) 
Anti-mold therapy during the previous 15 days (%) 17 (74) 16 (70) 1 (9) 
Serum GM antigen ≥ 0.5 (%) 15/23 (65) 9/23 (39) 6/11 (55) 
Positive mycological respiratory samplesa (%)    
At least one 15/19 (79) 4/16 (25) 9/10 (90) 
Bronchial aspirate 12/17 (71) 2/11 (18) 7/8 (88) 
Bronchoalveolar lavage fluid 9/17 (53) 2/13 (15) 6/7 (86) 
Lung CT scan findings (%)    
Angioinvasive diseaseb 3/23 (13) 10/22 (46) 1/10 (10) 
Invasive airway diseasec 10/23 (44) 3/22 (14) 2/10 (20) 
Invasive airway abnormalitiesd 13/23 (57) 5/22 (23) 4/10 (40) 
Any lesion except nodules with a halo sign or invasive airway abnormalities 7/23 (30) 7/22 (32) 5/10 (50) 
CharacteristicsAllogeneicstem celltransplantationN=23AcuteleukemiaN=23OtherN=11
Female gender (%) 8 (35) 15 (65) 4 (36) 
Age, years 37 (10 to 78) 53 (16 to 72) 64 (45 to 72) 
Type of diagnosis (%)    
Proven 2 (9) 1 (4) 1 (9) 
Probable 20 (87) 14 (61) 10 (91) 
Possible 1 (4) 8 (35) 0 (0) 
Concomitant lung infection (%) 11 (48) 1 (4) 4 (36) 
Bacterial 
Viral 
Fungal 
Corticosteroids (%) 19 (83) 6 (26) 6 (55) 
Absolute neutrophil count (ANC)/mm3 (%)    
<100 7 (30) 18 (78) 2 (18) 
100-500 5 (22) 1 (4) 4 (36) 
>500 11 (48) 4 (17) 5 (45) 
Anti-mold therapy during the previous 15 days (%) 17 (74) 16 (70) 1 (9) 
Serum GM antigen ≥ 0.5 (%) 15/23 (65) 9/23 (39) 6/11 (55) 
Positive mycological respiratory samplesa (%)    
At least one 15/19 (79) 4/16 (25) 9/10 (90) 
Bronchial aspirate 12/17 (71) 2/11 (18) 7/8 (88) 
Bronchoalveolar lavage fluid 9/17 (53) 2/13 (15) 6/7 (86) 
Lung CT scan findings (%)    
Angioinvasive diseaseb 3/23 (13) 10/22 (46) 1/10 (10) 
Invasive airway diseasec 10/23 (44) 3/22 (14) 2/10 (20) 
Invasive airway abnormalitiesd 13/23 (57) 5/22 (23) 4/10 (40) 
Any lesion except nodules with a halo sign or invasive airway abnormalities 7/23 (30) 7/22 (32) 5/10 (50) 
a

Culture, microscopy, or both;

b

at least one nodule with a halo sign without any invasive airway abnormalities (tree-in-bud opacities, ill-defined bronchocentric nodules, and/or centrolobular nodules);

c

invasive airway disease without angioinvasive disease;

d

presence of invasive airway abnormalities in association with any other lesion; GM, galactomannan

Results.

The presence of Aspergillus in respiratory samples was significantly more frequent in non-acute leukemia (AL) pts (83%) than in AL pts (25%) (p=0.0003), and in pts with ANC > 100/mm3 (p=0.0002). In a logistic regression model, these 2 factors appeared independent, with an adjusted OR of 7.27 (95% CI 1.42 to 37.3) for non-AL pts and an adjusted OR of 7.20 (95% CI 1.38 to 37.7) for ANC > 100/mm3. A positive mycological yield was detected in 95% of the non-AL pts with ANC > 100/mm3 vs. 23% of the AL pts with ANC < 100/mm3 (p=0.0002). A positive mycological result was also more frequent among pts with lung CT scan signs of invasive airway disease than among other patients (p=0.026). Furthermore, the CT scan findings were strongly associated with the underlying condition and ANC counts of the pt. In particular, invasive airway signs were significantly more frequent among non-AL pts (p=0.049), whereas angioinvasive disease was significantly more frequent among both AL pts (p=0.01) and patients with ANC < 100/mm3 (p=0.0001). Steroid therapy (yes/no and > or < 1 mg/kg) and previous anti-mold therapy had no significant effect on the results. Notably, a concomitant pulmonary infection was identified with bronchoscopy more frequently among non-AL pts (p=0.0009).

Conclusions.

We strongly recommend bronchoscopy for a specific diagnosis of aspergillosis among non-AL patients, particularly among allogeneic stem cell transplant recipients. Among AL pts with severe neutropenia, another diagnostic strategy should be considered.

Disclosures:

No relevant conflicts of interest to declare.

Author notes

*

Asterisk with author names denotes non-ASH members.

Sign in via your Institution